Japanese Society of Hematology conflict of interest management in medical research

Abstract

In March 2017, considering the recent social trend, the Japanese Association of Medical Sciences (JAMS) officially announced the “JAMS Conflicts of Interest (COI) Management Guideline” and the “JAMS Guidance on Criteria for Qualification to Practice Guideline.” In response to this announcement, the Japanese Society of Internal Medicine partially revised and announced the “Common Guideline on the Policy of COI in Medical Research,” including the “COI Management to Practice Guideline” and the “Treatment Guideline,” for its affiliated societies in September 2017. To ensure consistency with the Japanese Society of Internal Medicine, the Japanese Society of Hematology (JSH) has adopted and implemented the “Common Guideline of the Policy of COI in Medical Research of JSH,” which matches that of the Japanese Society of Internal Medicine, and revised “Bylaws Concerning Conflict of Interest Policy in Clinical Research of JSH” to “Disclosure of COI in Conferences or Official Journals of JSH.” Clinical Trials Act came into effect in April 2018, and the Japanese Ministry of Health, Labour, and Welfare has published “Guidance on COI Management according to Clinical Trials Act.”